Expanding our therapeutic options:  β-blockers for colon cancer? by Coelho, Marisa
  
ESCOLA SUPERIOR DE TECNOLOGIA DA SAÚDE DO PORTO 
INSTITUTO POLITÉCNICO DO PORTO 
 
 
MARISA ALEXANDRA ANTUNES COELHO 
 
EXPANDING OUR THERAPEUTIC OPTIONS:  
β-BLOCKERS FOR COLON CANCER?  
 
 
 
Dissertação submetida à Escola Superior de Tecnologia e Saúde do Porto para cumprimento 
dos requisitos necessários à obtenção do grau de Mestre em Tecnologia Bioquímica em Saúde, 
realizada sob a orientação científica da Professora Doutora Laura Ribeiro e co-orientação 
institucional do Professor Doutor Rúben Fernandes. 
 
setembro de 2013
  
 
  
  
  
À minha família 
"Se as raízes estão bem, todo o resto está bem."  
Peter Sellers 
 
  
i 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
ii 
 
AGRADECIMENTOS  
À Professora Doutora Laura Ribeiro, toda a orientação, incentivo e dedicação. Por 
todo o tempo disponibilizado, pela simpatia e por todo o conhecimento que me transmitiu. 
Por todo a apoio e confiança que depositou no meu trabalho. Por me incentivar a 
prosseguir quando os contratempos pareciam não acabar. Pela possibilidade de investigar 
este tema. 
Ao Departamento de Bioquímica da Faculdade de Medicina da Universidade do 
Porto e a todas as pessoas que dele fazem parte. Por me terem dado todas as condições 
técnicas e humanas necessárias para a conclusão de todo o trabalho que desenvolvi. 
Ao Departamento de Farmacologia e Terapêutica da Faculdade de Medicina da 
Universidade do Porto, em especial à Engª. Paula Serrão e à Engª Joana Afonso por toda a 
simpatia e disponibilidade sempre que precisei.  
À Reitoria da Universidade do Porto e ao Banco Santander Totta pela valorização 
da investigação jovem universitária e pelo financiamento deste projeto PP-IJUP2011-320.  
A todos os meus bons amigos agradeço a partilha de experiências, o ânimo, o 
alento, as boas conversas e a amizade sincera. Àqueles que estão cá desde sempre. Aos que 
fiz ao longo deste percurso, em especial ao André Cabral e ao Pedro Coelho pela preciosa 
ajuda e amizade durante este ano. Ao Carlos, toda a paciência, motivação e partilha. 
E por último mas mais importante que tudo, a toda a minha Família, a quem devo 
tudo o que sou. Às minhas princesinhas Nónó e Inês pela responsabilidade das minhas 
melhores gargalhadas. À minha cunhada Ana. À minha mãe e ao meu irmão por serem os 
melhores seres humanos que conheço. 
 
FINANCIAMENTO 
Supported by U. Porto/Santander Totta (IJUP) (PP-IJUP2011-320) 
  
iii 
 
 
  
  
iv 
 
PUBLICATIONS UNDER THE SCOPE OF THIS THESIS  
Communications to scientific meetings 
Marisa Coelho, Gustavo Correia, Miguel Moz, Ana Luísa Teixeira, Rui Medeiros, Laura 
Ribeiro. Expanding our therapeutic options: adrenergic beta-blockers for colon cancer?  
IJUP- 6th Meeting of Young Researchers at UP. Porto, February 13-15, 2013. 
M. Coelho, M. Moz, G. Correia, A. Sarmento-Cabral, A. Teixeira, R. Medeiros, L. 
Ribeiro. “Adrenergic receptor agonists and inverse agonists: role in the HT-29 human 
colon cancer cell line.” Neuroimmune Pharmacology: Challenging Paradigms Beyond 
Boundaries - Integrating pharmacology, immunology, and neurosciences in a therapeutic 
perspective. November 15-16, 2013, Center of Research in Medical Pharmacology, 
University of Insubria, Italy. (BEST POSTER AWARD) 
M. Coelho, M. Moz, G. Correia, A., A. Teixeira, R. Medeiros, L. Ribeiro. “Role of beta-
adrenergic receptor in a human colon cancer cell line.” ASCB Annual Meeting, 
December 14-18, 2013, New Orleans, LA, USA. 
 
Conference Proceedings 
Coelho M, Moz M, Correia G. Teixeira AL, Medeiros R, Ribeiro L. Role of beta-
adrenergic receptor in a human colon cancer cell line. Mol Biol Cell (accepted for 
publication).  
Coelho M, Moz M, Correia G, Sarmento-Cabral A, Teixeira AL, Medeiros R, Ribeiro L. 
Adrenergic receptor agonists and inverse agonists: role in the HT-29 human colon cancer 
cell line. Journal of Neuroimmune Pharmacology (accepted for publication).  
 
  
v 
 
 
  
  
vi 
 
ABSTRACT 
 Colon cancer is the fourth and third most common cancer, respectively in men and 
women worldwide and its incidence is increasing. Stress response has been associated to 
the incidence and development of cancer. The catecholamines (CA), adrenaline (AD) and 
noradrenaline (NA), are crucial mediators of stress response, exerting their effects through 
interaction with α- and β- adrenergic receptors (AR). Colon cancer cells express β-AR and 
their activation has been implicated in carcinogenesis and tumor progression. Recently, 
interest in the efficacy of β-AR blockers as possible additions to cancer treatment 
paradigms has been gaining strength.  
 The aim of this work was to investigate the effect of several AR agonists and β-
blockers, upon cellular proliferation and viability of HT-29 cells, a human colon 
adenocarcinoma cell line. For this purpose, in the first phase of this work, we determined 
the EC50 and IC50 values for proliferative and antiproliferative effects, respectively of AR 
agonists and antagonists. Afterwards, HT-29 cells were incubated in the absence (control) 
or in the presence of the AR-agonists, AD, NA and isoprenaline (ISO) (0.1-100 µM) for 12 
hours or 24 hours.  All tested AR agonists revealed proliferative effects upon HT-29 cells. 
In order to study the effect of several β-blockers upon both proliferation and viability 
induced by AR activation, cells were treated with propranolol (PRO; 50 µM), carvedilol 
(CAR; 5μM), atenolol (ATE; 50 μM), or ICI 118,551 (ICI; 5 μM) for 45 minutes prior, and 
simultaneously, to the incubation with each of the AR agonists, AD and ISO, both at 1 and 
10 μM. 
 Our results suggest that adrenergic activation play an important role in colon cancer 
cells proliferation most probably through β-AR. All the β-blockers under study were able 
to revert the proliferation induced by AD and ISO, and some of them, per se, significantly 
decreased the proliferation of HT-29 cells. The elucidation of the intracellular pathways 
involved in CA-induced proliferation of colon cancer cells, and also in the reversion of this 
effect by β-blockers, might contribute to reveal promising strategies in cancer treatment.  
 
Key words: Stress, catecholamines, adrenergic receptors, β-blockers, cell proliferation. 
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RESUMO 
 O cancro do cólon é o quarto e terceiro cancro mais comum, respetivamente nos 
homens e nas mulheres em todo o mundo, e a sua incidência está a aumentar. A resposta ao 
stresse tem sido associada a um aumento da incidência e desenvolvimento do cancro. As 
catecolaminas (CA), adrenalina (AD) e noradrenalina (NA) são os principais mediadores 
da resposta ao stresse, exercendo os seus efeitos através da interação com os recetores 
adrenérgicos (RA), α e β.  As células do cancro do colon expressam predominantemente os 
RA do tipo β, e a sua ativação está implicada na carcinogénese e na progressão dos 
tumores. Recentemente, tem sido notório o interesse na eficácia dos RA do tipo β como 
possíveis adjuvantes para o tratamento do cancro.  
O objetivo deste trabalho foi investigar o efeito de vários agonistas para os RA, e de 
β-bloqueadores, na proliferação e viabilidade de uma linha celular de adenocarcinoma de 
colon humano, as células HT-29. Para este efeito, na primeira fase deste trabalho, 
determinámos os valores dos EC50 e IC50, respetivamente para o efeito proliferativo e 
antiproliferativo dos agonistas e antagonistas dos RA em estudo. Posteriormente, as células 
foram incubadas na ausência (controlo) e na presença dos agonistas, AD, NA e 
isoprenalina (ISO) (1-100 µM) durante 12 ou 24 horas. Todos os agonistas em estudo 
aumentaram significativamente a proliferação das células HT-29. Para estudar os efeitos de 
vários β-bloqueadores na proliferação e na viabilidade induzida pela ativação dos RA, as 
células foram tratadas com propranolol (50 µM), carvedilol (5 μM), atenolol (50 μM) ou 
ICI 118,551 (5 μM) 45 minutos antes, e em simultâneo, do tratamento com cada um dos 
agonistas AD e ISO a 1 e 10 μM.  
Os nossos resultados sugerem que a ativação adrenérgica desempenha um papel 
importante na proliferação das células do cancro do cólon, muito provavelmente através 
dos recetores β. Todos os β-bloqueadores testados foram capazes de reverter a proliferação 
das células HT-29 induzida pela AD e pela ISO, sendo que alguns deles por si só 
diminuíram significativamente a proliferação destas células.  
A elucidação das vias envolvidas na proliferação de células de cancro do cólon induzida 
pelas CA, e também na reversão deste efeito pelos β-bloqueadores, pode contribuir para 
revelar estratégias promissoras no tratamento do cancro.  
Palavras-chave: Stresse, catecolaminas, recetores adrenérgicos, β-bloqueadores, 
proliferação celular. 
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Figure 1. Incidence and mortality of the ten most common cancers in the worldwide (more and less 
developed regions) for both sexes. (GLOBOCAN 2008, IACR)  
1. INTRODUCTION  
1.1. Cancer 
 Cancer is defined as a group of diseases characterized by uncontrolled growth and 
spread of abnormal cells. This pathology can be caused by both external and internal 
factors that may act together or in sequence to initiate or promote cancer (1). Despite the 
genetic and molecular events that accelerate or inhibit cancer induction is known best ever, 
cancer continues to kill millions of people worldwide (1).  
 Cancer is a leading cause of death in economically developed countries and the 
second leading cause of death in developing countries. The incidence of cancer is 
increasing in economically developing countries, not only as result of population aging and 
growth but also by the adoption of lifestyles associated with cancer like physical inactivity, 
smoking, and consumption of “westernized” diets (2). In 2008, worldwide is estimated to 
have occurred about 12.7 million cancer cases and 7.6 cancer deaths, of which 56% of the 
cases and 64% of the deaths in the economically developing world (2) (Figure 1).  It is 
estimated that 1 of each 3 persons is affected by cancer all over the world, ten million new 
cases are diagnosed each year, and it is predictable that this number will double in the next 
20 years (3).  
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Carcinogenesis is a multistep process that comprises genetic alterations that 
ultimately lead to progressive transformation of normal into malignant cells. This 
transformation requires alterations in cell physiology to promote the development of tumor 
cells. Hanahan & Weinberg (2000) (4) defined the following six hallmarks of cancer: self-
sufficiency in growth signals, insensitivity to growth-inhibitory (antigrowth) signals, 
evasion from programmed cell death (cellular apoptosis), limitless replicative potential, 
sustained angiogenesis, and invasion and metastasis (4). In 2011, the same authors 
proposed two new emerging hallmarks: deregulation cellular energetics and avoidance of 
immune destruction, and two enabling characteristics: genome instability and mutation and 
tumor-promoting inflammation (5).  
1.2. Coloretal Cancer 
 Colorectal cancer (CRC) is the third most common cancer in men representing 10% 
of the total, and the second most common cancer in women, about 9,4% of total worldwide 
(6). Significant variations have been observed in the distribution of CRC (7), but nearly 
60% of the cases occur in developed regions (6). The highest incidence rates of colorectal 
cancer are found in Europe, North America and Oceania whereas the lowest rates of CRC 
are found in Asia and South America (7) as we can see in Figure 2. Almost 608,000 deaths 
from CRC are predictable worldwide, which represents about 8% of all of deaths from 
cancer making it the fourth most common cause of death from cancer (6). The highest 
mortality rates in both sexes are estimated in Central and Eastern Europe and the lowest in 
Middle Africa (6). The majority of CRC are thus nonhereditary and sporadic, which makes 
early detection important. Most of the cases are identified at advanced stages, rendering 
curative treatment impossible (8). 
The main modifiable risk factors for CRC include overweight and obesity, red and 
processed meat consumption, excessive alcohol consumption, smoking, physical inactivity 
(2), and non-modifiable risk factors, are age, family history inflammatory bowel diseases 
(e.g. ulcerative colitis and Crohn’s disease) (9). 
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Figure 2. a) Incidence and b) distribution of colorectal cancer among both sexes for all ages (per 100.000) in 
2008 (GLOBOCAN 2008, IACR) 
 The progression of CRC includes several genetic and molecular alterations in cell 
proliferation, cell survival, differentiation, resistance to apoptosis, metastasis and 
angiogenesis (9). The progression cascades involve the accumulation of mutations of genes 
as well as the alteration of morphological and cellular events. These processes are 
commonly characterized by histologically distinct steps, this is, colonic crypt hyperplasia, 
dysplasia, adenoma, adenocarcinoma, and distant metastasis. In tumororigenesis of CRC 
several genetic alterations can be involved, an example is the oncogenic mutation of K-ras 
which results in Ras and its downstream effectors, such as Raf/MEK/ mitogen-activated 
protein kinase (MAPK) and phosphatidylinositol-3 kinase (PI3K)/Akt pathways (9,10). 
Another important singnalling pathway involved in tumorogenesis of CRC is the 
stimulation of Wnt/β-catenin/Tcf4 pathway which is triggered by the loss of Adenomatous 
polyposis coli (APC) function, mutation and constitutive activation of β-Catenin and K-
ras. This pathway, in turn, causes the transcription of downststream genes such as ciclin 
D1, myc, vascular endothelium growth factor (VEGF) and matrix metalloproteinases 
(MMPs), all important factors involved in carcinogenesis (9). Epidermal growth factor 
receptor (EGFR) signalling and transforming growth factor-β  pathway also involved in 
regulating colonocyte growth and differentiation, and are upregulated in hiperproliferative 
aberrant crypt foci as well as contribute to malignant growth of colon cancer (9).  
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In recent years new therapeutic targets have emerged namely inhibition of iNOS, 
COX-2, 3-hidroxi-3-metilglutaril-coenzima A (HMG-CoA), retinoid X receptor-α, 
estrogen receptor-β, β-catenin, 5-lipoxygenase (5-LOX), signal transducer and activator of 
transcripton-3 (STAT-3), and metalloproteinase (MMPs) (8,9). These therapeutic strategies 
have shown protective effects against CRC development in different animal models 
suggesting that they are crucial targets for mucosa inflammation and colon carcinogenesis 
(8,9). Prognosis in CRC patients is highly dependent on disease stage at diagnosis. 
Screening has become a compelling strategy for prevention of colorectal tumors and was 
shown to reduce CRC mortality, although  only 40% of cases are diagnosed at early stages 
(11).  
Human colon is particularly sensitive to stress because of the close distribution of 
noradrenergic fibers to its basement lamina (12). The expression of β-adrenergic receptors 
(AR) has been identified on colon cancer cells, and several studies have shown that their 
activation has been implicated in carcinogenesis and tumor progression in various types of 
colon cancer cells in vitro (12–15). Consequently the interest in the efficacy of β-blockers 
as possible additions to cancer treatment paradigms has been gaining strength recently (16–
18). However, it is not yet clear which of these drugs can be useful for these purposes. 
1.1. Stress and Allostatic Systems 
Stress is an inevitable element of our lives. Hans Selye, a pioneer in the approach of 
principles of physiology and pathophysiological of stress, defined stress as “the 
nonspecific response of the body to any demand” and Distress as “stress that is unpleasant 
or harmful to the body” (19–21).The physiologist Walter Cannon, introduced for the first 
time the terms Homeostasis and fight-or-flight response (21,22). Cannon also proposed that 
both adrenal medulla and sympathetic nervous system (SNS) operate as a unit and that 
adrenaline (AD) is not only the active mediator of the adrenal medulla but also a 
neurotransmitter of the SNS (21,22). 
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 Recently, Goldstein et al.(1990) proposed a new definition of stress: “Stress is a 
condition in which expectations, where genetically programmed, established by prior 
learning, or deduced from circumstances, do not match the current or anticipated 
perceptions of the internal or external environment, and this discrepancy between what is 
observed or sensed and what is expected or programed elicits patterned, compensatory 
responses ”, and of Distress: “is a form of stress with additional defining features-
consciousness, aversiveness, observable signs, and pituitary-adrenocortical and 
adrenomedullary activation” (21,23).  
 The maintenance of homeostasis, a complex dynamic equilibrium, is constantly 
challenged by intrinsic or extrinsic, real or perceived adverse forces, the stressors, and it is 
this control that allows life to exist (24). The term Allostasis was introduced by Sterling 
and Eyer (25) to refer the process of adaptation of the body upon the exposure to various 
stressors (21), this is, the process whereby an organism maintains physiological stability by 
changing parameters of its internal milieu by appropriately matching them with  
environmental demands (25,26). Adaptations involving allostasis are determined by 
genetic, developmental and experiential factors (23).  Allostatic load represents the “wear 
and tear” the body experiences when repeated allostatic responses are activated during 
stressful events  (23,26). Changes in homeostasis often produce not only neuroendocrine 
and physiological effects but also behavioral responses (27). 
 Stress can be either acute or chronic, respectively when is short-lived, or when is 
repetitive, or occurring over an extended period of time (28). Stress is an intricate process 
involving environment and psychosocial factors that trigger multiple information 
processing pathways in central nervous system (CNS) and periphery. The activation of 
these physiological stress coordinated responses prepares an individual to survive to a 
threat were thus deemed adaptive (29), but if these responses are inadequate or excessive 
and/or prolonged, may affect personality development and behavior, and may have adverse 
consequences on physiologic functions, such as growth, metabolism, circulation, 
reproduction and inflammatory/immune responses (24). These pathways trigger fight-or-
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flight stress responses in the autonomic nervous system (ANS), or defeat/withdrawal 
responses induced by the hypothalamic-pituitary-adrenal axis (HPA) (30).   
 Despite psychology has elaborated sharp distinctions between concepts such as 
stress, distress, depression and social isolation, the biological responses have not been 
differentiated in the framework of biobehavioral oncology research (31). Thus, Lutgendorf 
et al. (2011) (31) described all of these terms as “biobehavioral risk factors” to convey the 
general phenomenon that biobehavioral process appear to systematically impact a variety 
of important hallmarks of cancer biology (31). 
1.2. Stress Responses 
 Stress responses are mediated by the system of stress which includes both central 
and peripheral components. In the hypothalamus and brainstem are located the central 
components of the stress system and  the peripheral limbs of the HPA axis, together with 
the efferent sympathetic/adrenomedullary system, represent the peripheral components of 
this complex system (24). Stress exposure involves differentiated responses of the SNS and 
adrenomedullary hormonal systems depending on the type and intensity of the stressor, 
how it is sensed by the organism and interpreted in light of the previous experience (27) 
Currently, stress is not recognized as a disease but as a triggering factor for the majority of 
diseases when allostatic overload is generated (32). 
 In response to stress, glucocorticoids and CA are the main mediators released after 
activation of the hypothalamus-pituitary-adrenal cortex axis and SNS, respectively. 
Currently it is accepted that each stressor triggers its own neurochemical prolife, contrary 
the general notion described by Cannon and Selye that response to stress is primitive and 
unspecific. SNS activation predominates in response to orthostasis, moderate exercise, and 
exposure to cold, whereas adrenomedullary hormonal system predominates in response to 
glucoprivation and emotional distress (27).  
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Thus, NA levels, and thereby overall sympathetical nervous “activity” would play 
key roles in the appropriate distribution of blood volume and in the homeostasis of blood 
pressure (or blood delivery to the brain), during orthostasis, cold exposure, mild blood loss, 
locomotion, exercise, altered salt intake, and water immersion. On the other hand, 
adrenomedullary system activation and AD release occur in response to global or 
metabolic threats, such as hypoglycemia, hemorrhagic hypotension, heavy exercise, 
asphyxiation, emotional distress and shock (24,27).  
1.2.1. The Hypothalamic-Pituitary-Adrenal Axis (HPA)  
 The principal hypothalamic regulator of the HPA axis is corticotropin release 
hormone (CRH) a 41-amino acid peptide. This peptide stimulates the secretion of 
adrenocorticotropin hormone (ACTH) from the anterior pituitary. A synergistic factor of 
CRH is arginine vasopressin, also produced by the Hypothalamus. ACTH regulates the 
secretion of glucocorticoids, such as cortisol, by adrenal cortex namely by zona fasciculata, 
and also adrenal androgen by the zona glomerulosa (24,29). As previously mentioned, the 
final effectors of HPA axis are glucocorticoids that can influence metabolism, growth, 
immune function and also play an important role in regulation of basal function and stress 
reactivity in different organs. Depending on the stressor, other factors may be secreted, 
which potentiate HPA axis activity, such as angiotensin II, cytokines and lipid mediators of 
inflammation that may act on hypothalamic, pituitary, and/or adrenal components (24).  
1.2.2. The Sympathetic Adrenomedullary System (SAMS) 
 The ANS responses to stress are fast and control a wide range of functions being 
mediated primarily by the activation of the SNS from sympathetic neurons and the adrenal 
medulla (24,33). The sympathetic adrenomedullary system (SAMS) include the SNS and 
the adrenal medulla.  The SNS is organized into a central component, the pre-ganglionic 
neuron located in spinal cord. The peripheral component is a postganglionic neuron, 
situated into sympathetic ganglion, being activated by pre-ganglionic neurons and acts 
directly on structures and target organs through the release of noradrenaline (NA). This 
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central component also enervates the adrenal medulla to release mainly adrenaline (AD), 
into the bloodstream, but also NA, both having systemic effects (24,34,35). The SNS 
innervates widely  the smooth muscle of the vasculature, the heart, skeletal muscles, 
kidney, gut, fat and many other organs (24).  
 A fast response evoked by adrenergic system is critical to survival; however, 
prolonged activation of these pathways have deleterious consequences on several systems 
ultimately leading to the development of several pathologies. 
1.3. Stress and Cancer 
 The association between stress and cancer has a long history. In 200 AD, Galen 
suggested that women with a “melancholic” disposition were more susceptible to cancer 
than women with a more “sanguine” disposition (36). In the recent years, clinical and 
epidemiological studies have recognized that biobehavioral factors such as stress is a risk 
factor for the development and progression of several types of cancer (28,31,36). 
1.3.1. Epidemiological Studies 
 In recent years, the relationship between stress and cancer has been widely studied. 
There are a large number of epidemiological studies that investigated the association 
between stress related psychosocial factors and cancer outcomes, however many of them 
are inconclusive and contradictory. Some studies show that stress increases the risk of 
cancer and mortality (37), contrary to others that do not find this association (38). 
 A recent meta-analysis (39) that studied the relationship between stress and various 
types of cancer, show that studies available in the literature are very heterogeneous and 
have many and important methodological limitations. This systematic review confirmed 
using meta-analytic methods that stress and related psychosocial factors are associated 
with adverse effects on cancer incidence, survival and mortality. These associations 
differed depending on study characteristics such as sample size, follow-up period, quality 
score cancer type of psychosocial factor and cancer location. The authors found that 
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studies with longer follow-up periods had more expressive associations (39). The 
variability of studies associating stress with cancer are mainly due the difficulty in 
evaluating the response generated by a negative event. Indeed, most of the instruments like 
structured questionnaires to assess the number and intensity of stressors are subjective. 
Therefore, results obtained with these instruments should be complemented with biological 
parameters such as plasma levels of the stress hormones, AD, NA and cortisol to enable 
objectively determine the relationship of stress and cancer (39). This meta-analysis 
suggests by its results that stress-related psychosocial factors have in fact an adverse effect 
on cancer outcomes, although effects vary by type of psychosocial factor, cancer site and 
cancer outcome (39).  
1.4. Catecholamines 
  CA actions influences many functions practically in all tissues of the organism. CA 
are biogenic amines that possess a catechol group with an attached amino group 
(27,40,41). The non-essential amino acid L-Tyrosine (Tyr) is the precursor of CA 
synthesis. The  two primary sources of Tyr, are diet and hydroxylation of the amino acid 
phenylalanine in liver (21). Upon entry into an adrenal chromaffin cell or sympathetic 
nerve terminals, Tyr is converted to dihydroxyphenylalanine (DOPA) by tyrosine 
hydroxylase (TH), a soluble cytoplasmic enzyme which catalyzes the rate-limiting step of 
CA synthesis. TH use tetrahydrobiopterin (BH4) as cofactor and molecular oxygen to 
generate DOPA, dihydrobiopterin, and water (42). DOPA is converted into dopamine (DA) 
by a nonspecific enzyme, aromatic L-amino acid decarboxylase (AAAD), also known as 
Dopa decarboxylase (DDC), which uses pyridoxal phosphate as cofactor. After, DA is 
taken up from the cytoplasm into storage vesicles and converted into NA by dopamine-β-
hydroxylase (DβH). A percentage of this enzyme is released simultaneously with NA and 
AD by exocytosis.NA is converted into AD by phenylethanolamine N-methyltransferase 
(PNMT) a soluble cytoplasmic enzyme that uses S-adenosyl-methionine as cofactor. The 
main location of this enzyme is the adrenal medulla, but is also present in sympathetical 
innervated organs and some brain areas that are able to synthetize small amounts of AD 
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(21,43) (Figure 3). The biologic effects of the CA, AD and NA, are mediated by the AR α 
and β, which show different patterns of tissue distribution (41).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Pathway for catecholamine biosynthesis. In catecholamine synthesis, tyrosine hydroxylase 
catalyzes the conversion of the amino acid tyrosine to DOPA. Then, DOPA is converted to dopamine by 
dopa decarboxylase. In chromaffin granule, dopamine is converted to noradrenaline by dopamine-β-
hydroxylase. Finally, in the cytoplasm, phenylethanolamine N-methyltransferase catalyzes the conversion of 
noradrenaline to adrenaline. Adapted from Richard Kvetnansky et al.(21). 
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1.4.1. The role of catecholamines in the pathogenesis of cancer 
As previously referred, cellular and molecular events that promote cancer growth 
can be affected by stress, being CA important mediators in this process (33). AR, more 
specifically the β-AR,  have been identified in several tumor cell lines (33). 
A solid tumor, as colon cancer, is innervated by sympathetic nerve fibers like an 
integrated organ. Adrenergic nerve cells and nerve fibers exist and branch profusely into 
tumor tissues. However, the functions of these fibers in the tumor microenvironment have 
not been extensively studied. Neurotransmitters as CA are released upon the stimulation 
from sympathetic nerve fibers and are spread into tumor microenvironment. Tumor 
microenvironment and multiple physiologic processes of tumor development may be 
controlled by SNS. Biological behaviors of tumor and of stroma cells can be modulated by 
signalling of neurotransmitters by binding to respective receptors present in these cells 
(44).  
Over the last years the biological effects of stress pathways on cancer progression 
have been focused on studying the effects of stress hormones on tumor cell proliferation 
and apoptosis, tumor invasion and metastasis, tumor angiogenesis, stroma cells in the 
microenvironment and cellular immune responses (Figure 4) (28). The regulation of cancer 
cell development by neurobiological signals expands the opportunities for pharmacological 
interventions in cancer therapy. 
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1.4.1.1. Proliferation and apoptosis 
Human cells to acquire tumorigenicity must to overcome two barriers, replicative 
senescence and cellular crisis in order to achieve immortalization (22). Essential 
characteristic of cancer cells are the ability to sustain chronic proliferation and resistance to 
apoptosis (5). In normal tissues, the cell number control is exerted by production and 
 Figure 4. Stress responses on tumor microenvironment. Stress response results in the activation of autonomic 
nervous system (ANS) and the hypothalamic-pituitary–adrenal axis causing the release of AD, NA and 
cortisol, respectively. The tumoral microenvironment can be altered by these mediators enhancing cellular 
proliferation, migration, invasion, and angiogenesis contributing to tumor progression. Adapted from 
Lutgendorf et al (28). 
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release of growth signals that regulate the cell growth and cellular division cycle 
maintaining the normal functions of tissues and architecture (5). By deregulating these 
signals cancer cells become under an uncontrolled cell division state. These signals, 
typically growth factors that bind cell-surface receptors, emit signals through several 
signalling pathways. These pathways regulate not only cell cycle and growth and lastly 
progression, but also survival and energy metabolism (5). An effective treatment strategy 
for tumors may be the control of cellular proliferation (17). 
In 1989, Schuler and Cole (45) provided the first evidence that the β-AR agonist 
isoprenaline (ISO) promotes a significant increase in the proliferation of lung 
adenocarcinoma cells. In addition, these researchers also demonstrated that this effect was 
inhibited by propranolol (PRO), a β-adrenergic antagonist, commonly used in clinical 
setting (45). After this study, other reports have shown that the CA, AD and NA, and the β-
AR synthetic agonist ISO, through the activation of AR trigger signalling pathways that 
induce cell proliferation. Indeed, several in vitro and in vivo studies have shown that AD 
and NA can induce cell proliferation in different types of cancer such as non-small cell 
lung carcinoma (46) , ovarian cancer (47) , colon cancer (12) and oral squamous carcinoma 
(48). 
 The actions of CA upon tumor cells appear to be mediated primarily by β2-AR 
activation involving the cellular cyclic adenosine-3,5-monophosphate (cAMP) - protein 
kinase A (PKA) signalling pathway (49). Nevertheless, Thaker et al (2006) (47) also 
reported in an elegant paper that AD stimulate directly the proliferation of an esophageal 
cancer cell line through the β1/β2-AR/Extracellular signal-regulated kinase (ERK)/ 
Cyclooxygenase-2 (COX-2) pathways, β1 dependent kinases, and also AR-dependent 
upregulation of cyclins and cyclin-dependent kinases (50). In breast cancer cells, Carie and 
Sebti (51) showed in vitro and in vivo studies that  ARA-211, a β2-selective AR agonist, 
leads to a reduction of cell proliferation and tumor growth by blockade of the Raf-1/Mek-
1/Erk1/2 pathway  (51).  
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 In human gastric cancer cells was shown that nitrosamine 4-(methylnitrosamino)-1-
(3-pyridyl)-1-butanone (NNK) enhance cell proliferation and that PRO was able to block 
this effect. In addition, atenolol (ATE)  and ICI 118,551 blocked the regulatory action of 
nicotine on the PKC/ERK1/2/COX-2 pathway suggesting that β-AR are involved through 
this pathway in the promotion of gastric cancer development (49,52). 
 Prostate tissue has a high amount of β-AR, and several studies have demonstrated 
that β-AR agonists can stimulate adenylyl cyclase (AC) and increase cAMP levels in rat 
and human prostate cancer cell lines. These results show that β-AR, particularly β2-AR, 
through these pathways play an important role in carcinogenesis (49,53).  
 In ovarian carcinomas, in patients with biobehavioral risk factors, an increase 
activity of several β-adrenergically-linked transcription control pathways such as cAMP 
response element-binding (CREB)/AKT, activate nuclear factor κ-B (NF-кB) and STAT 
family transcription factors was observed (54). Furthermore, in these patients was also seen 
an increase of intra-tumor levels of NA, indicating that these biobehavioral risk factors 
might be linked with higher levels of CA and consequently with a more invasive into 
pattern of ovarian cancer (55). These effects in ovarian cancer cells are primarily mediated 
by β2-AR, via cAMP-PKA signalling pathway  (55). 
 In rat C6 glioma cells, ISO stimulate cell proliferation, whereas PRO cause a 
significant decrease of proliferation. Moreover, when these cells were treated with TNF-α, 
the gene expression and protein levels  of β1 and  β2  increased (56). 
Some studies also have studied the effect of β-AR agonists on colon cancer. In one 
of these studies was shown that NA and ISO stimulate the proliferation on  HT-29 (human 
colorectal adenocarcinoma) cells and that cAMP levels were increased by β-activation with 
ISO treatment, and this effect was significantly decreased with ICI 118,551 (14). In  a 
more recent paper, the same authors demonstrate that AD also affect HT-29 cells 
proliferation in a concentration-dependent manner, and both β1 and β2- AR selective 
antagonists, ATE and ICI respectively, revert this effect (12). 
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 Apoptosis (programmed cell death) is often mediated by anoikis, occurring when 
anchorange-dependent cells become separated from matrix extra cellular (57). Anoikis can 
be mediated by both intrinsic and extrinsic apoptotic pathways. Cancer cells acquire the 
ability to resist anoikis, and this resistance is one of most important hallmarks of malignant 
transformation (5,58). Tumor cells become able to survive in absence of matrix attachment 
and facilitating migration, reattachment and colonization of secondary sites (31,58). 
Indeed, in vitro and in vivo studies have shown that CA can protect ovarian cancer cells 
from anoikis being this effect mediated by focal adhesion kinase (FAK). FAK is a tyrosine 
kinase that stimulates cell adhesion and it is activated by NA through phosphorylation of 
pFAKY397. Tumor tissue from depressive patients with ovarian cancer present higher levels 
of NA and pFAKY397(31).  
1.4.1.2. Angiogenesis 
 Tumors stimulate the growth of host blood vessel, through a process called 
angiogenesis (59). This process, i.e. the growing of new blood vessels, is essential for 
supplying nutrients to tumor, for its growth, but also for metastization (59,60). Many 
factors  are able to promote angiogenesis, including vascular endothelial factor (VEGF), 
interleukin-6 (IL-6) transforming growth factor α and β (TGF-α/β) and tumor necrosis 
factor α (TNF-α) (28). In normal physiology, angiogenesis is a process intricately balanced 
between the proangiogenic and antiangiogenic factors, however in pathological conditions 
such as cancer, this balance is lost, leading to the formation of abnormal vessels with 
increased permeability (61). 
 Recently, it has been shown that stress hormones may promote angiogenic 
mechanisms (29,61). In fact, the synthesis of many proangiogenic factors in tumor cells is 
up-regulated by AD and NA by acting through β-AR. Thaker et al. in 2006 (47) 
demonstrated that NA stimulates angiogenesis in human ovarian tumors (Hey-A8, 
SNOV3ip1) growing orthotopically in nude mice by acting through β2-AR expressed in 
these tumor cells (47,61). In these malignant ovarian tumors, the signalling pathway 
through angiogenesis occurs is described as β-AR→cAMP→PKA→VEGF (47,61). Also 
Expanding our therapeutic options: β-blockers for colon cancer? INTRODUCTION 
 
 
19 
 
in these tumors, it was found that NA and isoproterenol induced the expression of VEGF 
(28,62). In human pharyngeal carcinoma cells line (HONE 1) and in several human 
multiple myeloma cell lines (NCI-H929, MM-MI and FLAM-76) similar results were 
observed (63,64). Another important proangiogenic molecule, IL-6, is also involved in 
NA- and AD-mediated ovarian cancer angiogenesis (48). Recently, in human ovarian 
tumor cells (Hey-A8, SNOV3ip1 and EG) an increase of the synthesis and release of IL-6 
was shown after treatment with NA. The authors confirmed the involvement of NA and β-
AR on this effect through the use of β-AR antagonists, which were able to abolished NA 
effect (61,65). In this case, the proposed pathway in human ovarian tumor cells is NA→ β-
AR → Src kinase→ IL-6. Src kinase is over expressed in human cancer ovarian tissues 
with increased tumor neovascularization. Furthermore, in human ovarian tumor cells the 
VPF / VGEF and IL-8, proangiogenic molecules are induced by Src, suggesting that CA 
are responsible for regulating the synthesis of the proangiogenic molecules in this model 
(48,61). 
 Recently, other studies also have shown that the signal transducer and activator of 
transcription factor-3 (STAT-3) that is activated by growth factors and cytokines, such as 
VEGF and IL-6, can be involved in angiogenesis in tumor stress-mediated. AD and NA, 
induce the expression, cellular localization and activation of STAT3 (29,66).  
 Interestingly enough, among the endogenous molecules recently identified as 
potential targets for future therapeutics, CA have been of recent interest due to their actions 
in the regulation of the angiogenic process (40).  
1.4.1.3. Migration and Invasion 
 The ability of cancer cells to separate from the original tumor, invade through the 
basement membrane and enter the bloodstream is a key step in the metastatic cascade (28). 
The process by which tumor cells intrude the host basement membrane consists of multiple 
steps that involve attachment, matrix dissolution, motility and then intrusion (29).  
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 There are several lines of evidence suggesting that stress hormones can be involved 
in this important step of cancer progression, contributing to tumor cell movement and 
invasion (29). CA can influence these processes by increasing the production of MMP by 
cancer cells and by acting as chemoattractants to induce cell migration (28,67).  
 MMP are enzymes secreted by tumor cells but also by stromal cells that facilitate 
the breakdown and remodeling of the extracellular matrix by degrading components of the 
extracellular matrix, such as elastins, fibronectines, laminins, collagen and the protein core 
of proteoglycans enabling the tumor to spread locally or distantly (68). It has been shown 
that the expression of MMP is modulated by stress hormones. For instance, in an ovarian 
carcinoma, in vitro model, the use of NA mimicking stress conditions, increased the 
production of MMP-2 and MMP-9 and the potential invasion of cancer cells, being this 
effect inhibited by the β-adrenergic antagonist, PRO, suggesting the involvement of β-AR. 
Furthermore, ISO used in vivo simultaneously with PRO, was able to substantially reduce 
tumors size (68). 
 In colon carcinoma cells (SW 480 cells), NA was capable to induce migration that 
was reverted with the β-adrenergic antagonist PRO but not with a β1-selective adrenergic 
antagonist, ATE. This finding suggest that the use of β2-blockers might inhibit metastasis 
and the progression of colon cancer (15). Other studies have reported similar findings in 
several other tumor types such as nasopharyngeal carcinoma model (63) prostate cancer 
(69) and breast cancer (70). Stress hormones might directly regulate the growth and 
metastatic potential of tumor cells, and this effect might be independent of the immune 
system (47). 
 All of these findings provide important evidences that stress hormones can promote 
cell invasion in different types of cancer and that β-blockers can revert this effect.  
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1.5. Adrenergic Receptors, β-blockers and cancer 
 As already mentioned throughout this introduction, CA exert their effects by 
interacting with receptors α and β-AR. 
 The activation of these AR trigger several pro-angiogenic signalling pathways 
encouraging cancer growth by cell proliferation, evasion of apoptosis, invasion, 
angiogenesis and metastasis (35). 
1.5.1. Adrenergic Receptors 
 AR are targets for many therapeutically important drugs such as that used for 
cardiovascular diseases, asthma, prostatic hypertrophy, nasal congestion obesity and pain 
(71). These receptors are divided in two main classes: α and β. Each group is further 
subdivided in two main α-receptor subtypes, α1 and α2, and three β-receptor subtypes, β1, 
β2 and β3. In total, there are nine subtypes of α-AR: α1A, α1B, α1D, α2 A/D, α2B, α2C. Other two 
AR candidates were recently described (α1L and β4), that may be conformational states of 
α1A and β1-AR, respectively (72). (72) 
 AR are coupled to second-messenger systems via G proteins (71,72). G-protein-
couple receptors (GPCRs) like the AR are characterized by the presence of seven 
membrane spanning α-helical segments (73). These segments are separated by alternating 
intracellular an extracellular loop regions (Figure 5). Despite these similarities, individual 
GPCRs have unique combinations of signal-transduction activities involving multiple G-
protein subtypes, as well as G-protein-independent signalling pathways and complex 
regulatory process (73). 
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1.5.1.1. α-AR 
As mentioned before, the α-AR are subdivided into two main classes α1 and α2 
(Table 1). α1-AR are found in bladder, uterus, gastrointestinal tract, bronchi, and smooth 
muscle of the blood vessels. α1-AR are mainly coupled to Gq/11 protein and lead to the 
stimulation of phospholipase C activity (71,74). Phospholipase C promotes the hydrolysis 
of phosphatidylinositol bisphosphate producing inositol trisphosphate (IP3) and 
diacylglycerol (DAG) which act as second messengers (71). α1-AR is also involved in the 
activation of MAPK (74). 
 α2-AR are predominantly coupled to the inhibitory G proteins, Gi and G(o), 
inhibiting the activity of AC, and consequently decreasing intracellular cAMP levels  
leading to membrane hyperpolarization(71). α2-AR when located presynaptically have a 
role as modulator of neurotransmission inhibiting the release of NA and acetylcholine. 
They also cause platelet aggregation, contraction of vascular smooth muscle and inhibition 
of insulin release (74). α2-AR are found at post-junctional or non junctional sites in several 
tissues, and thus their activation may also lead to the trigger of other intracellular pathways 
such as the activation of phospholipase A2, C, and D, with arachidonic acid mobilization, 
 Figure 5. Structure of adrenergic receptors (AR). AR have extracellular amino terminals with sites for N-
linked glycosylation, seven α-helical domains that are each thought to span membrane and intracellular 
carboxy terminals containing aminoacids sequences creating three intracellular  and three extracellular loop 
domains. Adapted from Insel (1996) (107). 
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increasing in phosphoinositide hydrolysis, and increase in the intracellular availability of 
Ca2+. In addition, α2-AR can activate MAPKs (71). However, some of the effects of α2-AR 
are independent of their ability to inhibit AC (71). 
Table 1. α-AR subtypes: α1, α2, α3 and main transduction signals and rank of order of potency of agonists and 
selective antagonists. Adapted from (Alexander SPH et al., 2011) (72) 
 
1.5.1.2. β-AR 
β-AR are constitutively expressed in most mammalian cells and are related with 
several regulatory pathways operating under conditions of stress (49). 
 The three β-AR subtypes are encoded by three different genes located on human 
chromosomes 10 (β1), 5 (β2), and 8 (β3) (75) (Table 2). β-AR show distinct patterns of 
distribution and signal through distinct biochemical pathways (76,77). They bind both to 
AD and NA, as well as to exogenously drugs, including synthetic β-agonists like ISO and 
also to several antagonists, commonly termed β-blockers (75).  
Nomenclature α1 α2 
 α1A α1B α1D α2A α2B α2C 
Other names α1a,  α1c α1b α1A/D,  α1a/d  α2D -   - 
Principal 
transduction 
Gq/11 Gi/o 
Rank order of 
potency 
AD=NA AD>NA 
Selective 
antagonists 
Tamsulosin, 
silodosin, 
(+)niguldipine, 
SNAP5089 
- BMY7378 BRL44408  Imiloxan  
JP1302 
Oxymetazoline 
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 β1-AR are predominantly found in the heart where their activation results in as 
increased rate and force of contraction whereas in the sphincter muscle of the gut their 
activation leads to relaxation (78). 
β2-AR when activated in smooth muscle leads to vasodilation, whereas activated in 
bronchial smooth muscle leads to bronchodilatation. Activation of β2-AR also promotes 
relaxation of visceral smooth muscle, hepatic glycogenolysis and muscle tremor (71,78). 
 β3-AR are found in the adipose tissue where they initiate lipolysis in white adipose 
tissue, with the release of fatty acids and glycerol to the circulation. These AR are also 
involved in thermogenesis process in the brown adipose tissue. Although also present in 
heart, their functions in this organ are not fully known (71,79). 
Table 2. β-AR subtypes: β1, β2, β3, respective main transduction signals and rank of order of potency of 
agonists and selective antagonists. Adapted from (Alexander et al., 2011) (72) 
 
In the context of cancer, the three β-AR subtypes are present at many sites related 
with tumor growth and metastasis process namely in brain, lung, liver kidney, colon, 
adrenal gland, breast, ovary, prostate, lymphoid tissues, bone marrow and vasculature. β-
AR signalling also regulates the function of several cancer-relevant cell types such as 
epithelial cells, vascular myocytes and pericytes, fibroblasts, immune cells, adipocytes and 
neuronal and glial cells (76,77). 
Nomenclature β1 β2 β3 
Other names - - atypical β 
Principal transduction Gs Gs Gs 
Rank order of potency ISO> NA> A ISO > A>>NA ISO ~ NA > A 
Selective antagonists Atenolol ICI 118,551  
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Figure 7. (A) Expression of mRNA levels by RT-PCR assay of β1, β2 and β3 - AR mRNA levels in CRC HT29, 
SW116 and LS174T cells. (B) Expression of protein levels by Western blot analysis of β1 and β2 - AR in CRC 
HT29, SW116 and LS174T cells T29, SW116 and LS174T cell lines by western blot analysis (82). 
The first evidence of β-ARs as regulators of cancer cells was provide by Schuller et 
al in 1989 (80). This study showed a significant increase in the proliferation of human lung 
adenocarcinoma cells in response to ISO, and that this response was inhibited by PRO 
(80). 
In 2005, William et al. (14) characterized the expression of both β1 and β2 in several 
colon cancer cells (Figure 6) and showed that mRNA expression of both receptors was 
detected in HT-29, SW1116 and SW480. Indeed, these authors confirmed that HT-29 cells 
strongly expressed β2-AR mRNA and that β1-adrenoceptor expression is just barely 
detectable (14).  
 
 
 
 
 
 
Figure 6. RT-PCR analysis revealed the expression of β1 and β2-AR in three colon cancer cell lines including 
HT-29. 50bp marker; +, β-actin; -, negative control (PCR product without reverse transcription (14)). 
More recently, another study confirmed the detection of β1 and β2 mRNA levels, as 
well as protein levels by Western blot in several  CRC cell lines, including HT-29 whereas 
β3-AR was not detected in these cells (Figure 7) (81). 
 
 
 
 
Expanding our therapeutic options: β-blockers for colon cancer? INTRODUCTION 
 
 
26 
 
Several cellular evidences show that β-AR are important mediators of growth, 
invasiveness and differentiation, making these receptors a promising  target for treatment 
and prevention  of various types of cancers. Several reports show the expression of β-AR 
in normal and malignant colon tissues; however, their modulatory action on cancer growth 
and their relationship to stress are still elusive. 
When CA binds to β-AR, activate the Gαs guanine nucleotide-binding protein to 
stimulate AC and the synthesis of cAMP. cAMP can regulate a diverse array of cellular 
process via two  major downstream effector systems (76) (Figure 8).  
The first one, consist of the activation of PKA by cAMP, which consequently 
phosphorylates serine or threonine residues on target proteins. Through this pathway 
several process are affected such as metabolism, growth, differentiation, morphology, 
motility, secretion, neurotransmission, and gene transcription for instance, the cAMP-
responsive element binding protein/activating transcription factor (CREB/ATF) family. 
Transcriptional alterations induced by PKA promotes cell differentiation and proliferation. 
Furthermore, PKA is also able to activate the β-adrenergic receptor kinase (BARK). 
BARK induces β-arrestin which desensitize β-AR signalling and activate the 
Src/Ras/MAPK pathway (76). 
The second effector system includes the guanine nucleotide exchange protein 
activated by AC (EPAC). EPAC activates the Ras-like guanine triphosphatase Rap1A. 
Rap1A stimulates the downstream effectors B-Raf, MAP/extracellular signal-regulated 
kinase (ERK) 1/2, and ERK1/2. β-adrenergic influences on inflammation, angiogenesis, 
invasion and proliferation appear to be mediated by PKA induction of genes encoding 
cytokines and growth factors. EPAC induces complementary but distinct effects on cell 
morphology and motility (76). 
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Figure 8. Main β-adrenergic signaling pathways in cancer. The stress hormones, adrenaline (AD) and noradrenaline 
(NA), bind to β-ARs, resulting in Gαs-mediated activation of adenylyl cyclase and subsequent cAMP synthesis. cAMP 
effectors involve the activation of  both PKA and exchange protein activated by adenylyl cyclase (EPAC). In the first 
one, PKA phosphorylates multiple target proteins, including transcription factors of the CREB/ATF and GATA families, 
as well as β-AR kinase (BARK). BARK recruitment of β-arrestin inhibits β-AR signalling and activates Src kinase, 
resulting in activation of transcription factors, such as STAT3. In the second via, the activation of EPAC leads to Rap1A-
mediated activation of the B-Raf/mitogen-activated protein kinase signalling pathway and downstream effects on diverse 
cellular processes, including gene transcription mediated by AP-1 and Ets family transcription factors. The general 
pattern of transcriptional responses induced by β-adrenergic signalling include the upregulation of expression of 
metastasis-associated genes involved in inflammation, angiogenesis, tissue invasion, and the downregulation of 
expression of genes facilitating antitumor immune responses. Besides the direct effects on β-receptor-bearing tumor 
cells, β-adrenergic effects on stromal cells in the tumor microenvironment generally synergize with direct effects on 
tumor cells in promoting cancer survival, growth and metastatic dissemination. Adapted from Steven W. Cole and Anil 
K. Sood (2011) (76). 
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1.5.2. β-blockers 
β-blockers are used for various therapeutic indications such as hypertension, 
tremors, management of cardiac arrhythmia, migraines and cardioprotection after 
myocardial infarction (17,77). In fact, β-blockers have a long history of use in humans for 
the treatment of hypertension and cardiovascular disorders (49). 
 Classically, drugs that modulate β-AR are through to stabilize the proportion of 
receptors that are in an active signaling conformation relatively to those in an inactive, 
non-signaling conformation. Thus, whereas an agonist induces a certain receptor 
conformation, which leads to its activation, an antagonist stabilizes the inactive 
conformation. This binary categorization underestimates the true complexity of receptor 
ligand behavior (82).Actually, now it is recognized that there are more than two possible 
conformations for β -AR and that their activation can trigger more than one signaling 
pathways, namely heterotrimeric G-proteins and β-arrestin (82,83). In addition, AR ligands 
preferentially signal through either the G protein- or β-arrestin-mediated pathway (i.e. 
display bias towards one pathway over the other) (84,85). This behavior gave rise to the 
new concept of biased agonism (82). In fact, β-blockers are not merely antagonists for G-
protein pathway, but they may indeed independently modulate the two pathways and 
behave as partial agonist, inverse agonists or pure antagonists in each pathway(84). Biased 
agonism might have outstanding implications for β-AR blockers therapeutic use in cancer, 
since distinct signaling through these parallel pathways is thought to have distinct 
functional consequences (84). In fact, β-AR blockers could act as antagonists of G protein-
mediated functions, but evoke different effects upon β-arrestin-mediated signaling (84). 
This could result in markedly different effects in vivo, and may even explain the distinct 
efficacy profiles of β-AR blockers in the treatment of various cardiovascular diseases (86). 
For example, clinical trials assessing the efficacy of these drugs in the treatment of 
congestive heart failure revealed that carvedilol, metoprolol and bisopropol, but not 
bucindolol, decreased mortality, and the reason for the lack of beneficial action of 
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bucindolol remains elusive (84). In a similar way, in cancer, it is crucial to investigate 
which β-AR blockers are more effective in antagonizing the effects promoted by CA. 
As already mentioned, there are several studies showing that β-blockers have 
significant antitumorigenic effects at various stages of carcinogenesis such as in control of 
cell proliferation, angiogenesis and metastasis in some cancers such as breast (87), lung 
(46), pancreas (88), prostate (89), colon (12,15),  stomach (52) and ovarian cancer (68). 
1.5.2.1. Epidemiological Studies 
A number of retrospective population studies suggested that β-blockers may have a 
protective role in reducing the incidence and progression of some cancer types (17). 
The first clinical evidence that reported in humans the protective effect of β-
blockers in the treatment of breast cancer was provided by Powe et al. (2010) (90). These 
authors studied patients with breast cancer, who were treated for hypertension with or 
without β-blockers (90). The group under β-blocker medication demonstrated a significant 
reduction in distant metastasis and tumor recurrence, and a 71% reduction in cancer-
specific mortality. After this study, Ganz et al.(2011) (91), analyzed the association 
between β-blockers and breast cancer recurrence, breast cancer-specific mortality and 
overall mortality, concluding that woman taking β-blockers show a nonsignificant 14 % 
reduction in the risk of breast cancer recurrence, a nonsignificant 24% reduction in the risk 
of cancer specific mortality, and no reduction in all-cause mortality (91). A population 
study of Barron  et al. (2012) (92) compared women diagnosed with stages I and IV 
invasive breast cancer, taking either PRO, ATE or not taking β-blockers. The findings of 
this study reveal that PRO users were significantly less likely to present a T4, node-
positive or metastatic disease, whereas ATE users had no significant differences in T4, 
node-positive, and breast cancer specific mortality. In other study, Melhem-Bertrandt et 
al.(1999) (60) reviewed patients with breast cancer who received neoadjuvant 
chemotherapy, concluding that among β-blockers metoprolol and ATE, were the most 
commonly  prescribed. When these authors compared β-blockers use with pathological 
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complete response, relapse-free survival and overall survival, they concluded that β-
blocker use was not associated with pathological complete response, but was associated 
with a significantly better relapse-free survival, mainly among patients with triple-negative 
breast cancer (60).  
β-blockers also seem to have an important role on infantile hemangioma (IH). This 
tumor, characterized by the abnormal proliferation of endothelial cells and angiogenesis is 
the most common form of vascular tumor, affecting 5% to 10% of all infants and up to 
30% of premature infants (93). In 2008, Léauté-Labrèze et al (2008) (94) showed that PRO 
had an anti-proliferative effect in severe IH. After this study, others researchers verified 
that other β-blockers were effective at controlling IH growth. In a randomized, double-
blind, placebo-controlled, parallel-group trial conducted by Hogeling et al (2011) (95) 
PRO users were more likely to show a significant reduction in both tumor volume and 
redness. Another blinded cohort study by Pope et al (2012) (96), studied the efficacy and 
safety of nadolol, a nonselective β-blocker with no intrinsic sympathomimetic activity, in 
patients with IH and concluded that patients treated with nadolol had a more favorable 
response and fewer parental reports of minor adverse events, than patients who were 
treated with PRO (96). 
Two retrospective studies, by De Giorgi et al.(2011) (97) and Lemeshow et 
al.(2011) (98), studied the association between exposure of melanoma patients to β-
blockers and survival.  In the study of De Giorgi et al.(2011) (97) authors concluded that β-
blocker treatment was inversely associated with recurrence, and that there was a significant 
reduction in the risk of relapse. Regarding the study of Lemeshow et al.(2011) (98), the 
authors showed that in melanoma patients receiving β-blockers (including metoprolol, 
PRO and ATE) a significant reduction of mortality due to melanoma and all-cause 
mortality was observed. 
With regard  to colon cancer, in a recent population-based case control study, 
Jansen L. et al (99) did not find association between CRC risk and the use of β-blockers. 
However, they found in β-blockers a lower risk of stage IV CRC.  
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2. AIM 
 This work aimed to investigate the effects of several adrenergic agonists and 
antagonists upon cellular dynamics, namely proliferation and viability, of colon cancer 
cells. For that purpose, the effect of these drugs was investigated, using the colon cancer 
cell line, HT-29.  
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3. MATERIALS AND METHODS 
3.1. Compounds and Treatments 
The adrenergic agonists, AD (Adrenaline - L-Adrenaline (+)-bitartrate salt), NA 
(Noradrenaline - L-(−)-Noradrenaline (+)-bitartrate salt monohydrate) and ISO 
(Isoprenaline - (−)-Isoprenaline (+)-bitartrate salt) and the adrenergic antagonists, PRO 
(Propranolol - DL-Propranolol hydrochloride), ICI (ICI118,551-(±)-1-[2,3-(Dihydro-7-
methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-butanol hydrochloride) and ATE 
(Atenolol-(±)-4-[2-Hydroxy-3 [(1methylethyl)amino] propoxy] benzeneacetamide were 
purchased from Sigma (St. Louis, MO, USA) and CAR (Carvedilol-1-(9H-Carbazol-4-
yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)-2-propanol) from Enzo Life Sciences, Inc., 
Farmingdale, NY, USA. 
For the treatment of cells with the several drugs under study, stock solutions of 
each compound were prepared (1 or 10 mM) with the corresponding solvents (AD and 
ISO: H2O; PRO and ATE: ethanol (0.1% (v/v); CAR and ICI: DMSO (dimethylsulfoxide) 
(0.1% (v/v)).  Corresponding controls were prepared with the solvent for each drug 
dissolved in FBS-free medium, and FBS-medium was the positive control. AD and NA 
concentrations used in the experiments reflect the levels described in tumors. To determine 
the effects of the adrenergic agonists AD, NA and ISO on HT-29 cells proliferation and 
viability, cells were incubated for 12 or 24 hours with these drugs at 0.1 µM, 1 µM, 10 µM 
and 100 µM. In order to study the effects of β-blockers over AD and ISO actions, cells 
were pretreated with PRO, CAR, ATE and ICI 45min prior, and simultaneously with, to 
treatment with the adrenergic agonists. The β-blockers to be tested were selected based not 
only on their prevalent use in pharmacological studies and clinical settings, but also by 
their distinct affinity for β-AR and efficacy in modulating several signalling pathways. 
Expanding our therapeutic options: β-blockers for colon cancer? MATERIALS 
AND 
METHODS 
 
 
39 
 
3.2. Materials 
RPMI 1640 medium (Gibco, Portugal), Fetal Bovine Serum (FBS) (St. Louis, MO, USA), 
Penicillin, Streptomycin, (St. Louis, MO, USA); trypsin-EDTA. Cell Titer 96 Aqueous 
ONE Solution Reagent (MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium], colorimetric assay (Promega, Madison, EUA); Cell 
Proliferation ELISA BrdU kit (Roche Diagnostics, Portugal); MTT ((3-(4,5-di-methyl-
thiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (Sigma, St. Louis, MO, USA). Ethanol 
and DMSO (Invitrogen Corporation, CA, USA.). 
3.3. Cell Culture 
Human colon adenocarcinoma HT-29 cells were kindly provided by Prof. Bruno 
Sarmento (INEB) and Prof. Fernando Magro (FMUP). HT-29 cells were cultured in RPMI 
1640 medium supplemented with 10% of FBS, 100U/mL penicillin and 100µg 
streptomicyn. Cells were grown at 37ºC in a humidified 5% CO2 atmosphere. Culture 
medium was changed every 2–3 days.  Once the cells reached 90–100% confluence, 
medium was removed, and cells monolayer was washed with PBS. The cell monolayer was 
treated with 1 mL of 0.25% (w/v) trypsin-EDTA and incubated 2 minutes to ensure 
complete cell detachment. For sub-culturing, cells were sub-cultured in plastic culture 
dishes (21cm2; Ø 60mm; Corning Costar, Corning, NY). For the experiments, HT-29 cells 
were seeded into 96-well (0.37 cm2, Ø 6.9 mm, TPP) or 24-well plastic cell culture 
clusters (2cm2 Ø 16mm; TPP), depending on the experimental conditions. The experiments 
were performed 4-5 days after the initial seeding (90–100% confluence). 
3.4. Viability experimental studies 
3.4.1. Trypan blue exclusion assay 
Cellular viability was determined by the Trypan Blue exclusion assay, and 
experiments were only performed when viability was higher than 90%. In brief, cells were 
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trypsinized and stained with 0.4% trypan blue and viable cells counted with a 
hemocytometer. 
3.4.2. MTS assay 
HT-29 cells were seeded at 1× 105 cells/mL in 96-well plates for 24 hours, and 
afterwards incubated with each drug for 12 or 24 hours, depending on the experimental 
conditions. Cell viability was assessed using the Cell Titer 96 Aqueous ONE Solution 
Reagent (MTS colorimetric assay, according to the instructions provided by the 
manufacturer). Briefly, culture medium was removed and the cells were preincubated with 
the test compounds dissolved in culture medium at 37°C for 12 or 24 hours. After 
removing this medium, cells were incubated for 3 h with 100 µL of FBS-free culture 
medium and MTS. 
Absorbance was measured at 492 nm. Results were expressed as percentage of 
control. 
3.4.3. MTT assay 
The effect of β-blockers on cellular viability was assessed by the MTT method. The 
MTT assay is based on mitochondrial dehydrogenase activity. Indeed, mitochondrial 
dehydrogenases of viable cells cleave the tetrazolium ring, yielding purple formazan 
crystals, which are insoluble in aqueous solutions. The amount of these formed products 
was determined spectrophotometrically. Briefly, after the incubation periods with the 
several drugs, cells were washed once with PBS and exposed to a MTT solution at a final 
concentration of 5mg/ml for 3h and then lysed with DMSO. Absorbance was measured at 
540nm. All samples were assayed in triplicated and at least in three independent 
experiments, and the mean value for each experiments was calculated. The results are 
given as mean (± SEM) and are expressed as percentage of control. 
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For determination of the half maximal inhibitory concentration (IC50), the 
concentration that reduces the effect by 50%, of the several drugs under study, and the half 
maximal effective concentration (EC50) values, the concentration that gives half maximal 
response, cells were seeded into 96-well plates at a density of 1×104 cells/well for 24 
hours, and then incubated for 24 hours with increasing concentrations of the various 
compounds (0.1, 1, 5, 10, 20, 50 and 100 µM). Cells were then washed twice with warm 
PBS and incubated with MTT (0.5 mg/mL) for 2 h at 37 °C. Blue formazan crystals were 
solubilized by adding 100 µl DMSO/well, and the colored solution was subsequently read 
at 550 nm. Results are expressed as % of MTT reduction compared to untreated control 
conditions (adapted from Juranic et al. (100)). 
3.5. Proliferation experimental studies  
Cell proliferation was assessed as DNA synthesis. To evaluate DNA synthesis, the 
incorporation of either ³H-thymidine or of 5' bromodeoxyuridine (BrdU) into DNA was 
determined.  
3.5.1. Incorporation of ³H-Thymidine 
HT-29 cells were seeded for attachment at 5×104 cells/well into 24-well (1.65 cm2; 
∅ 14.5 mm; Orange Scientific, Belgium) plastic cell culture clusters in a final volume of 
0.5 mL culture medium containing 10% FBS. After 24 hours in culture, cells were treated 
with different concentrations of the adrenergic agonists in culture medium (controls were 
made in the presence of culture media). After 24 hours, cells were incubated with 0.2 mL 
of methyl-[3H]-thymidine (0.5µCi/well) for 4 hours. The medium was removed and cells 
fixed by incubation in 0.3 mL of 10% TCA for 1 h at 4°C. The cells were then washed 
twice with 0.3 mL of 10% TCA to remove unbound radioactivity. The plates were air-dried 
and cells lysed with 0.28 mL/well of 1 M NaOH. A 0.25 mL aliquot of the lysate was 
neutralized with 0.050 mL of HCl prior to the addition of scintillation fluid. The 
radioactivity of the samples was quantified by a liquid scintillation counter. The counts 
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(disintegrations per min) of each treatment were averaged and expressed as the percentage 
of controls (adapted from (Miranda et al., 1999) (101). 
3.5.2. Incorporation of 5' bromodeoxyuridine (BrdU) 
  The incorporation of BrdU is a method based on the incorporation of the 
pyrimidine analogue BrdU, a thymidine analogue, instead of thymidine into DNA of 
proliferating cells. After its incorporation into DNA, BrdU is detected by immunoassay.  
 HT-29 cells were grown at 1×105 cells/ml in 96-well plates for 24 hours, and 
proliferation measured using the Cell Proliferation ELISA BrdU kit, according to the 
manufacturer’s instructions. Briefly, cells were labeled with BrdU (final concentration 10 
µM/well) for 12 hours at 37º C. Afterwards, cells were denatured with FixDenat solution, 
and then incubated for 120 minutes with 1:100 diluted mouse anti-BrdU conjugated to 
peroxidase. After removing the antibody conjugate, and washed twice with washing 
solution (PBS 1X), substrate solution was added for 25 minutes and the reaction stopped 
with 1 M H2SO4 solution. Absorbance was measured within 5 minutes at 450 nm with a 
reference wavelength at 690 nm using an ELISA plate reader. The blank corresponded to 
100 µL of culture medium without BrdU, and the control was made in the presence of 
culture media without any treatment. The results are given as mean (± SEM) and are 
expressed as percentage of control. 
For treatments during 24 hours, another protocol for BrdU assay was tested. 
Briefly, 5x103 cells per well were seeded in 96-well plate. The medium was supplemented 
with antibiotics plus 1% FBS for cell attachment, and then, cells were starved in serum-
free medium for another 12 hours to synchronize cell cycle. HT-29 cells were incubated 
with AD, ISO or NA (0, 1, 10 µM) for 24 hours to study the growth-promoting effect of 
these adrenergic agonists. To examine the effects of various β-blockers, cells were 
pretreated with or without the several adrenergic antagonists, PRO (50 µM), CAR (50 
µM), ATE (5 µM)  and ICI (5 µM) for 45 minutes prior to, and also simultaneously with, 
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AD or ISO treatment. Cell proliferation was indicated by the amount of DNA synthesis 
measured with the BrdU incorporation assay kit, according to the manufacturer’s 
instructions. Briefly, cells were labeled with 10 ml/well BrdU and incubated at 37°C for 4 
hours. After removal of the labeling medium, cells were fixed and probed with the anti-
BrdU monoclonal antibody at 25°C for 2 hours and its substrate tetramethyl-benzidine 
(TMB) at 25°C for 30 min. After removal of the unconjugated antibody, cells were rinsed 
3 times with the washing solution and treated with 200 µl/well substrate solution. After 
color development, 1 M H2SO4 was added (25 µl/well) to stop the substrate reaction, and 
the absorbance of each sample was measured in an enzyme-linked immunosorbent assay 
(ELISA) microplate reader at 450 nm (with a reference wavelength at 690 for blank to 
disccount the nonspecific binding to the anti-BrdU antibody). The value from the 
nonspecific binding was subtracted from all the other values. The results are given as mean 
(± SEM) and are expressed as percentage of control. 
3.6. Statistical Analysis 
The results are expressed as arithmetic mean  SEM. Differences in proliferation or 
viability between cells treated and corresponding untreated controls were tested using a 
Student’s t-test. For the calculation of EC50 and IC50 values, the parameters of the Hill 
equation were fitted to the experimental data by using a non-linear regression analysis, 
using a computer-assisted method (101). n represents the number of replicates of at least 
three different experiments. Comparisons between three or more groups were performed 
with one-way analysis of variance (ANOVA) followed by Tamhane or Bonferroni test. 
Differences were considered to be significant when p <0.05. 
Given the variability of the results on different days, each experimental data was 
adjusted to respective controls. 
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4. RESULTS 
In the present study, we intended to clarify the role of the stress hormones, AD and 
NA, and β-blockers in colon cancer cells proliferation by using a human colon 
adenocarcinoma cell line (HT-29 cells). Thus, using selective agonists and antagonists for 
β-AR, we investigated the differential involvement of these receptors, namely of β1 and β2, 
in colon cancer cells growth.  
To assess the effect of the adrenergic agonists, AD, NA and ISO on HT-29 cells 
proliferation as DNA synthesis we performed two assays: ³H-Thymidine incorporation (for 
treatments with these drugs during 12 hours) and BrdU incorporation (for treatments 
during 12 and 24 hours with these drugs and also for experiments with the several β-
blockers). 
To evaluate cell viability in cultured HT-29 cells in response to agonists and β-
blockers we used both MTS (for treatments during 12 and 24 hours with the AR agonists) 
and MTT assays (for the simultaneous exposure to agonists and β-blockers). 
4.1. Determination of EC50 values for the adrenergic agonists, 
adrenaline and isoprenaline, in HT-29 cell line 
In order to determine the EC50 values of AR agonists in this cellular model, HT-29 
cells were treated in control conditions (without drugs) and with increasing concentrations 
(0.1, 1, 5, 10, 20, 50 and 100 µM) of AD and ISO for 24 hours to determine the effects of 
these drugs on cellular growth. The above experiments generated concentration–response 
curves for both agonists (Figure 9) allowing to calculate the EC50 values (Table 3). Based 
on the concentration-response curves for both agonists, EC50 values were calculated, 
being 9.98 (0.51-197.2) and 29.27 (0.72-1194.0) µM, respectively for AD and ISO. 
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        Table 3. EC50 values for adrenaline and isoprenaline on HT-29 proliferation. 
 
4.2. Effect of chronic treatment (12 hours) with adrenergic agonists on 
HT-29 cells proliferation and viability 
The exposure of HT-29 cells to the adrenergic agonists AD, NA and ISO (at 
0.1μM-100μM) markedly increased the proliferation (Figures 10A and 11) and viability 
(Figure 10B) of these cells. After 12 hours, AD had its maximum effect on proliferation at 
10 µM (131.0 ± 8.7%, n=10), NA at 100 µM (146.3±17.1%, n=8) and ISO at 100 µM 
(150.9 ± 25.5%, n=7), relatively to controls (Figure 10A). In relation to the viability 
assessed by MTS (Figure 10B), only the positive control, with 10% FBS (CT+), and NA at 
100 µM significantly increased cellular viability comparing to controls.  
Cell type Agonist EC50 
 µM 
95% n 
HT-29  
Adrenaline 9.98 
      0.51 – 
197.2 
 
10-11 
Isoprenaline 29.27 0.72-1194.0 8-12 
Shown are the EC50 values with the corresponding 95% confidence intervals.  
Figure 9. Effect of adrenaline and isoprenaline on cell growth of HT-29 cells assessed by MTT assay after 
24 hours of treatment. Results are expressed as mean ± SEM and are normalized to 100% of control groups 
(without the drugs). 
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Figure 10. Effect of adrenaline (AD), noradrenaline (NA) and isoprenaline (ISO), at 0–100 μM, in human colon 
adenocarcinoma HT-29 cells proliferation (A) (n=6-12) and viability (B) (n=11-15), after incubation for 12 
hours. Cell proliferation was assessed by BrdU incorporation and cell viability by a MTS assay, as described in 
the Materials and Methods section. Results are expressed as mean ± SEM. *p<0.05 comparing to control. 
 
When the 3H-Thymidine incorporation assay was used (Figure 11), AD was able to 
increase proliferation by 18% (n=8) and 36% (n=6) respectively at 0.1 and 1.0 µM. NA at 
10 µM led to a significant increase of proliferation by 33% (n=6) and ISO increased 
proliferation at all concentrations tested (to 138%, 123% and 140%, respectively at 0.1, 1.0 
and 10 µM (n=5-7)). 
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Figure 11. Effect of adrenaline (AD), noradrenaline (NA) and isoprenaline (ISO), at 0–10 μM, in human 
colon adenocarcinoma HT-29 cells proliferation after incubation for 12 hours. Cell proliferation was assessed 
by using the 3H-Thymidine incorporation assay as described in the Materials and Methods section. Results 
are expressed as mean ± SEM (n=5-18). *p<0.05 comparing to control. 
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4.3. Effect of chronic treatment (24 hours) with adrenergic agonists on 
HT-29 cells proliferation and viability 
We further tested the effect of AD and ISO on cell proliferation, and also the effect 
of the three adrenergic agonists under study in cell viability at 24 hours (Figure 12). 
Chronic treatment (24 hours) with the AR agonists induced a significant increase of HT-29 
cell proliferation (Figure 12A). AD led to a significant increase of cell proliferation by 
164.7% (n=18) and 145.5% (n=18), when used at 1μM and 10μM, respectively, whereas 
ISO enhanced HT-29 proliferation by 46.1% (n=10) and 48.6% (n=15), respectively at 1 
and 10 μM, when compared to controls.  
In relation to viability assessed by MTS assay, as we can see in Figure 12B, the 
results obtained with the treatment during 24 hours were less consistent in comparison with 
the treatment during 12 hours (Figure 10B), given that for all the adrenergic agonists only a 
few of the used concentrations were effective in increasing HT-29 viability.  
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Figure 12. Effect of adrenaline (AD), noradrenaline (NA) and isoprenaline (ISO), in human colon 
adenocarcinoma HT-29 cells at 0–10 µM (n=6-18) on proliferation assessed by BrdU incorporation assay 
(A) and at 0–100 µM (n=3-14) on viability assessed by MTS assay (B) as described in the Materials and 
Methods section, after incubation for 24 hours. Results are expressed as mean ± SEM, *p<0.05 comparing 
to control. 
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4.4. Determination of IC50 values for β-blockers in HT-29 cell line  
In order to calculate the IC50 values (the drug concentration for 50% block) for the 
effect of β-blockers on cellular survival, cells were treated under control conditions 
(without drugs) and with increasing concentrations of either PRO, CAR, ATE or ICI (0.1, 
1, 5, 10, 20, 50 and 100 µM) for 24 hours. The concentration-response curves of cell 
proliferation are shown in Figure 13 and IC50 values in Table 3. 
As shown in Figure13, PRO potently inhibited the proliferation of HT-29 cells at 
concentrations over 50 µM, being its IC50 for PRO 65.4 µM. HT-29 proliferation was 
inhibited in a concentration-dependent manner by CAR after exposure during 24 hours. 
Among the β-blockers tested, CAR was proved to be the most potent with an IC50 of 8.0 
µM. ATE when used at the highest concentration (100 µM) significantly decreased HT-29 
survival being its IC50 value 52.9 µM. CAR and ICI showed similar IC50 values, 
respectively 8.0 µM and 8.9 µM.  
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Figure 13. Concentration-response curves for HT-29 cell survival. Cells were treated with increasing 
concentrations (0, 0.1, 1, 5, 10, 20, 50 and 100 µM) of each β-blocker, propranolol (PRO) (A), carvedilol 
(CAR) (B), atenolol (ATE) (C) and ICI 118,551 (ICI) (D) during 24 hours and viability was assessed by a 
MTT assay. Results are expressed as mean ± SEM and normalized to 100% of control groups (without 
drugs). *p<0.05 comparing to control.  
Table 4.  Effect of β-blockers on HT-29 proliferation 
Cell type β-Blockers 
IC50 
 µM 
95% n 
HT-29 
Propranolol 65.4 33.7 – 126.9 10-12 
Carvedilol 8.0 6.0 – 10.6 12 
Atenolol 52.9 21.7 – 128.7 6-12 
ICI 118,551 8.9 6.5 – 12.0 12 
Shown are IC50 values with the corresponding 95% confidence intervals.  
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4.5. Effect of β-blockers on HT-29 cells proliferation  
To elucidate the role of β-AR upon cell proliferation induced by AR activation, the 
agonists AD and ISO (a nonselective versus a β-selective agonist) were employed 
simultaneously with the following β-blockers PRO (50 µM), CAR (5 µM), ATE (50 µM) 
or ICI (5 µM).The concentrations used for β-blockers were selected based on the IC50 
values, previously calculated. 
4.5.1. Propranolol 
The role of β-ARs in proliferation is supported by the results presented on Figure 
14 where can be seen that PRO, a non-selective β-AR antagonist, abolished the 
proliferation increase induced by both AD and ISO. AD-induced cell proliferation was 
markedly reduced by PRO to 11.8 ± 3.4% (n=6) and 32.0± 9.7% (n=5), when AD was 
respectively used at 1 and 10 µM. Cells treated with PRO, at 50 µM, greatly decreased cell 
proliferation evoked by ISO to 20.1± 2.1% (n=5) and 23.3± 5.2% (n=5), when ISO was 
respectively used at 1 and 10 µM. Furthermore, as we can see in the same graph, PRO per 
se induced a significant proliferation decrease to 44.2± 9.6% (n=6), when compared with 
control group.  
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Figure 14. Effect of the non-selective β-adrenoceptor antagonist propranolol (PRO) at 50 µM on adrenaline 
(AD), 1 and 10 µM, and isoprenaline (ISO), 1 and 10 µM, induced HT-29 cell proliferation. Cells were 
pretreated with PRO for 45 minutes before incubation, and simultaneously with AD and ISO for 24 hours. 
Cell proliferation was measured by BrdU incorporation assay, as described in the Materials and Methods 
section. *p<0.05, significantly different from the untreated control group. #p <0.01, significantly different 
from the respective concentration AD-treated group and ++p <0.01 significantly different from the respective 
concentration ISO-treated group. 
4.5.2. Carvedilol 
The response profile of CAR, a potent non-selective β and α1-AR antagonist, in 
reverting the proliferative effects of both AD and ISO, was quite similar to the results 
obtained with PRO. Indeed, as shown in Figure 15, CAR was able to strongly inhibit the 
proliferative effect evoked by both agonists. 
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CAR decreased the proliferation induced by AD to 28% (n=6) and 56% (n=6), 
when AD was respectively applied at 1 and 10 µM, and to 27% (n=6) and 36% (n=6) when 
ISO at 1 and 10 µM was used. Contrary to PRO, CAR per se did not significantly affect 
the proliferation of HT-29 cells.  
 
 
 
 
 
 
 
 
 
 
Figure 15.  Effect of the non-selective β and α1-adrenoceptor antagonist carvedilol (CAR; 5 µM) on 
adrenaline (AD) at 1 and 10 µM, and isoprenaline (ISO), at 1 and 10 µM on HT-29 cell proliferation. Cells 
were pretreated with CAR for 45 minutes before incubation, and simultaneously with, AD and ISO for 24 
hours. Cell proliferation was measured by BrdU incorporation assay, as described in the Materials and 
Methods section. *p<0.05, significantly different from the untreated control group. #p <0.01, significantly 
different from the respective concentration AD-treated group and ++p <0.01 significantly different from the 
respective concentration ISO-treated group. 
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4.5.3. Atenolol 
To elucidate the role of β1-AR in HT-29 proliferation, we have used ATE, a β1 – 
selective antagonist, as previously mentioned for the other related experiments, before and 
simultaneously with the treatment with both AR agonists. Figure 16 shows that ATE 
significantly blocked AD and ISO-induced cell proliferation, confirming the involvement 
of β1 subtype in promoting tumor cell proliferation. ATE significantly decreased cell 
proliferation induced by AD at 1 and 10 µM to 55.7± 5.6% (n=6) and 53.4± 3.6% (n=6), 
respectively and to 45.8± 9.2% (n=6) and 32.1± 4.6% (n=6) for ISO respectively at 1 and 
10 µM. Furthermore, when applied alone, ATE decreased proliferation to 55.4± 13.9% 
(n=6), comparing to control.  
0
5 0
1 0 0
1 5 0
2 0 0
D
N
A
 s
y
n
t
h
e
s
is
 (
%
 o
f 
c
o
n
tr
o
l)
A D  1M
A D  1 0M
IS O  1M
IS O  1 0M
A T E  5 0M
-
-
-
-
-
+
-
-
-
-
-
+
-
-
-
+
-
-
-
+
-
+
-
-
+
-
-
+
-
-
-
-
-
+
-
-
-
+
-
+
-
-
-
+
+
-
-
-
-
+
*
* *
*
# #
+ +
+ +
*
 
Figure 16. Effect of the selective β1-adrenoceptor atenolol (ATE; 50 µM) on adrenaline (AD), at 1 and 10 
µM, and isoprenaline (ISO), at 1 and 10 µM, on HT-29 cell proliferation. Cells were pretreated with ATE for 
45 minutes before incubation, and simultaneously with AD and ISO for 24 hours. Cell proliferation was 
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measured by BrdU incorporation assay, as described in the Materials and Methods section. *p<0.05, 
significantly different from the untreated control group. #p <0.01, significantly different from the respective 
concentration AD-treated group and ++p <0.01 significantly different from the respective concentration ISO-
treated group. 
4.5.4. ICI 118,551 
To confirm the involvement of β2 –AR in HT-29 proliferation, cells were incubated 
with ICI, a β2–selective antagonist, either alone or with the AR agonists. As we can see in 
Figure 16, ICI did not significantly affect the proliferation induced by AD, whereas 
diminished to 64.1 ± 11.1% (n=7) the effect evoked by ISO 10 µM, reinforcing the 
involvement of β2 -AR subtype in this process. ICI per se had no effect on HT-29 cell 
proliferation. 
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Figure 17. Effect of the selective β2-adrenoceptor ICI-118,551 (ICI, 5µM) on adrenaline (AD), 1 and 10 
µM, and isoprenaline (ISO), at 1 and 10 µM, induced HT-29 cell proliferation. Cells were pretreated with 
ICI for 45 minutes before incubation, and simultaneously with AD and ISO for 24 hours. Cell proliferation 
was measured by BrdU incorporation assay, as described in the Materials and Methods section. *p<0.05, 
significantly different from the untreated control group. #p <0.01, significantly different from the respective 
concentration AD-treated group and ++p <0.01 significantly different from the respective concentration 
ISO-treated group. 
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 All together, these results suggest that PRO is the most effective β-blocker in 
reverting the proliferative effect of the adrenergic agonists under study, probably due to its 
ability to bind both to β1 and β2.  
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5. DISCUSSION 
Stress has been proposed to play a central role in the incidence and development of 
cancer (36). However, the molecular and cellular mechanisms by which stress increases the 
risk of some cancers and their prognosis remain understudied. Interestingly enough, it has 
been postulated that endogenous CA mediate the association between stress response and 
poor cancer outcomes (39,47). It hence appears that the most common human cancers are 
not only stimulated by stress neurotransmitters in the systemic circulation, but also produce 
their own CA. Moreover, growing evidences suggest that exposure to chronic stress 
impairs the immune system, alter cancer cell functions and tumor development (36,101). 
Epidemiologic studies also have associated the use of β-blockers in clinical settings to 
reduced rates of progression for several solid tumors (76). β-blockers are currently one of 
the most used drugs to treat angina and cardiac arrhythmias, as well as hypertension, 
cardiac failure, glaucoma, migraine and anxiety, but new therapeutic options have been 
advanced (77). Indeed, several findings suggest that β-AR blockers may be inexpensive 
and safe therapeutic agents for cancer, but their impact on cancer survival is not known. In 
the majority of the mentioned studies, no distinction was made between the use of β-
blockers with selective β1 or β2 receptor activity, and the signaling pathways implicated in 
these responses are poorly understood. 
In this study, we addressed the effect of the stress hormones, AD and NA, and ISO, 
a synthetic β non-selective agonist, and several β-blockers, on colon cancer cells 
proliferation, a critical component of the carcinogenesis cascade. As previously mentioned, 
CA exert their biological effects through binding to AR. In tumoral cells, β-AR are the key 
receptors in mediating the effects of CA. Indeed, the expression of β-AR has been 
identified in normal colon tissue and in colon cancer cells, including HT-29 cells, the 
experimental model used in this study, being β2-AR the predominant receptor subtype in 
these cells (14). In fact, several studies have recognized β-AR activation as a central 
mediator of stress effects on cancer growth. The activation of these receptors in a variety of 
cancer cell types in different tumorigenic processes, including tumor cell proliferation (12), 
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migration (15) apoptosis (110), angiogenesis (61) and differentiation (18). Therefore, β-AR 
blockade with pharmacological agents could potentially be used to alleviate the effects of 
stress upon cancer growth and progression. In line with this, some studies have found that 
β-AR blockade may suppress cancer cell invasion and inhibit adrenergic driven metastasis 
(88).  
In our study, the results obtained with the adrenergic agonists, not only confirmed 
that stress hormones affect colon cancer cells proliferation, but also suggest a prominent 
role for β-AR in this process. AD and ISO, as previously shown by other authors 
(12,14,81) significantly augmented HT-29 proliferation, most probably through β-AR. 
Indeed, both agonists have a high affinity for β-AR, strongly expressed in these cells, and 
in our study evoked a similar proliferative response. Based on the above observations, we 
explored the AR subtypes involved in AD and ISO effects, by using β-blockers with 
distinct profiles for AR. 
Our results show that the β-blockers under study significantly reduced the 
proliferation induced by both AD and ISO, reinforcing that these agonists mainly acted 
through β-AR. Altogether, our results clearly indicate the involvement of both β-AR 
subtype’s β1 and β2 in promoting colon cancer cell proliferation. PRO, the nonselective β-
AR antagonist, was the most potent β-blocker in reverting AD effects upon cell 
proliferation, probably by its ability to bind to both β1 and β2, as already highlighted by 
other reports (81). Indeed, the proliferation increase evoked by AD was strongly abolished 
by PRO, less by CAR, even less by ATE and was not affected by ICI. According to β2 
involvement in this effect, the β1-blocker (ATE) was a week antagonist for AD actions; 
however, the selective β2-blocker (ICI) had no effect. On the other hand, with the 
exception of ICI, which had a moderate effect, all the other β-blockers markedly inhibited 
the proliferation induced by ISO. Thus, contrary to other reports (12,14,81), ATE, the 
selective β1 antagonist, was more effective than the selective β2-antagonist, ICI, in 
reverting both AD and ISO induced cell proliferation. 
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As previously referred, β-blockers are not solely antagonists for the G-protein 
pathways, but they may indeed independently modulate more than one pathway, and 
behave as partial agonist, inverse agonists or pure antagonists in each pathway, increasing 
the complexity of their actions (82). Thus, biased agonism might have outstanding 
implications for β-AR blockers therapeutic use in cancer, since distinct signaling through 
these pathways is thought to have specific functional consequences (82). All the β-AR 
blockers tested were already recognized as being inverse agonists (84). The finding that 
both PRO and ATE used alone were able to decrease HT-29 cell proliferation, suggests 
that they acted as inverse agonists, a characteristic already described by some authors in 
other experimental models for both drugs acting via β1 and β2-AR (84). Activation of β-
ARs result in an increase of cAMP intracellular concentrations and cell proliferation, two 
processes reversed by treatment with either β1-or β2-AR antagonists (93). In fact, PRO and 
ATE acting as inverse agonists through binding to both β-AR lead to a decrease of cAMP 
accumulation (84), an outcome that could explain the proliferation decrease induced by 
these drugs in our study. On the other hand, neither the β2 selective agonist (ICI) nor CAR 
had an antiproliferative effect when used alone, despite both have been described as being 
able to diminish cAMP levels (102). Thus, as suggested by others (77), β-blockers seem to 
have complex profiles for cAMP modulation and Erk1/2 activation at both β1 and β2-AR. 
Moreover, CAR is able to activate different signaling pathways depending on the cell type 
(102), and till now its effect upon HT-29 proliferation was unknown. In fact, CAR behaved 
similarly to PRO when used simultaneously with both agonists, but, contrary to data 
obtained with other cell types for both β1 and β2, probably had no effect as inverse agonist.  
Several researchers have been studying the downstream signaling pathways 
involved in β-AR mediated tumor growth. Among the mammalian MAPK pathways, ERK 
is the best studied, and the deregulation of this pathway occurs in approximately one-third 
of all human cancers (103). Some studies have concluded that β-AR mediated ERK1/2 
activation could be one of the mechanisms underlying stress-induced cancer cell growth in 
vivo, suggesting for instance that β-AR blockade may be an effective approach for patients 
with stress-related colon cancer (81). On the other hand, in 2006, Shenoy et al (104) 
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showed in tumoral models that ISO through binding to β2-AR leads to the activation of a G 
protein- independent ERK pathway, but dependent on β-arrestin. Indeed, the pathway 
whereby growth factors and mitogens activate ERK signalling is of particular relevance to 
cancer (103). All the β-blockers used in our study, with the exception of ICI, were already 
described as being capable to activate ERK pathway. However, as referred before, when 
used alone, ATE and PRO decreased cell proliferation and CAR had no effect.  
Three of these drugs (CAR, PRO and ATE) are widely used clinically. In fact, 
similar studies have shown that these and other β-blockers reveal new clinical applications 
in medicine, which is very attractive for commercial purposes. On the other hand, 
deepening the knowledge of β signaling pathways involved in cancer may allow finding 
and selecting appropriate inhibitors both to prevent and treat cancer. In addition, 
corroborating the putative use of β-blockers as therapeutic agents in cancer, at least three 
phase II clinical studies assessing the safety and efficacy of β-blockers in breast, colorectal 
and ovarian cancers are currently running (105).  
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6. GENERAL CONCLUSIONS AND FUTURE WORK 
In conclusion, our work showed that all the adrenergic agonists tested increased the 
proliferation of HT-29 cells. All the β-blockers reverted, with less or more potency, the 
proliferative effect of the agonists, confirming the role of β-AR in cancer biology. This 
study reinforces several lines of evidence suggesting that stress hormones have an 
important role in carcinogenesis, namely in colon cancer proliferation, and that β-blockers 
can be used to revert these effects. 
Cancer cell proliferation is a complex process that involves several pathways and 
different molecules; therefore further approaches are essential to evaluate other β-blockers, 
and also the intracellular mechanisms underlying, not only the effect of endogenously CA, 
greatly released under stress conditions, but also of adrenergic agonists in clinical use. A 
better knowledge about these mechanisms might contribute to the discovery of new 
promising targets for cancer prevention and treatment.  
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